The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

URGN FINANCIAL STATEMENTS

UroGen Pharma Ltd — balance sheet, income statement and cash flow trends

URGNUroGen Pharma Ltd

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-100 M0100 M200 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue188.7 M $Gross Profit171.5 M $ · 91%Operating Income-66.7 M $ · -35%Pre-tax Income-98.1 M $ · -52%Net Income to Owners-97.6 M $ · -52%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue188.7 M $+100.3%
Gross Profit171.5 M $+105.5%
Operating Income-66.7 M $—
EBITDA-70.7 M $—
Net Income to Owners-97.6 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 M400 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets252.6 M
  • Current Liabilities61.9 M $16%
  • Long-term Liabilities323.1 M $84%

Key Figures

YoY change
Total Assets252.6 M $+21.0%
Total Liabilities385 M $+27.4%
Total Equity-132.4 M $—
Cash & ST Investments108 M $-31.2%
Total Debt196.1 M $+53.9%
Net Debt117 M $+238.5%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-150 M-100 M-50 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-150 M-100 M-50 M0-158.9 M $Operating40.1 M $Investing105.3 M $Financing-13.5 M $Net Change

Key Figures

YoY change
Operating Cash Flow-158.9 M $—
Capital Expenditures218 K $-44.9%
Free Cash Flow-159.1 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on URGN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.